Inactive Instrument

Baxalta Inc Share Price

Equities

End-of-day quote Nyse Other stock markets
- ^USD	-

2016	Baxalta : Shire jumps as Vyvanse drug helps it to beat earnings forecast	RE
2016	Baxalta : Shire director pay resolution just scrapes though at general meet	RE

Baxalta : Shire jumps as Vyvanse drug helps it to beat earnings forecast	29/16/29	RE
Baxalta : Shire director pay resolution just scrapes though at general meet	28/16/28	RE
Baxalta : Drugmaker Shire delivers earnings beat amid deal-making push	11/16/11	RE
Baxalta : Shire says internal synergy goals from Baxalta deal higher	13/16/13	RE
Baxalta : Drugmaker Shire buys Baxalta for $32 billion after six-month pursuit	12/16/12	RE
Baxalta : Drugmaker Shire buys Baxalta for $32 billion after six-month pursuit	12/16/12	RE
Baxter : Shire, Baxalta to announce merger as soon as Monday: sources	08/16/08	RE
Shire : closer to deal to buy Baxalta - sources (Exclusive)	23/15/23	RE
Baxter : Exclusive - Shire closer to deal to buy Baxalta: sources	23/15/23	RE
Baxalta : Exclusive: Shire prepares to make new bid for Baxalta - source	25/15/25	RE
Baxalta : Shire to buy Dyax for $5.9 billion, still wants Baxalta	02/15/02	RE
Baxalta : Shire to buy Dyax for $5.9 billion, still wants Baxalta	02/15/02	RE
Baxter : to cut 1,400 jobs worldwide to boost profits	27/15/27	RE
Baxalta : Shire's eye drug data could strengthen bid for Baxalta, says CEO	27/15/27	RE
Allergan : Eye drug setback hits Shire shares amid Baxalta pursuit	19/15/19	RE

Baxalta : Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions	03/16/03	PR
Baxalta : CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination	27/16/27	BU
Baxalta : OncoResponse Secures Investment from Baxalta	26/16/26	BU
Baxalta : Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)	25/16/25	BU
Baxalta : Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.	25/16/25	BU

Alcoa : Wall Street termine dans le désordre une séance volatile	12/16/12
Wall Street termine dans le désordre une séance volatile	12/16/12
Baxalta : Shire met la main sur Baxalta pour 32 milliards de dollars	12/16/12
Shire : met la main sur Baxalta pour environ $32 milliards	11/16/11
Baxalta : La valeur du jour à Wall Street - BAXALTA racheté par Shire pour 32 milliards de dollars	11/16/11

Sector

	1st Jan change	Capi.
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B